Don’t invest unless you’re prepared to lose all the money you invest. This is a high‑risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.


CoSyne Therapeutics

Co Syne Logo no background

There is a substantial unmet need for new drugs to treat brain cancer.​

Gliomas are the most common primary brain tumours. They cause 220,000 deaths per year globally. In high grade cases, 95% of patients die within 5 years.​

The best current drug (temozolomide) prolongs life expectancy by only 3 months yet generates £1 billion per year for Merck.​

A major problem is that gliomas are molecularly heterogenous. The result is that drugs that only target a subpopulation of cells drive evolution of drug resistance, leading to tumour recurrence.

CoSyne’s computational engine uses systems genomics to identify novel drug targets. They have applied this engine to neuro-oncology and have developed a platform to identify truncal drug targets that are highly conserved across cancer cells, thereby overcoming molecular heterogeneity and discovering novel synthetic lethal interactions.​

The platform outputs novel drug targets with paired genetic biomarkers, which allows us to develop precision therapeutics tailored to the exact molecular vulnerabilities in a specific patient’s cancer.​

​CoSyne’s platform can be scaled to discover new drug targets in a wide range of cancers and neurological diseases such as Parkinson’s Disease and Alzheimer’s Disease.​

Start Codon were the initial investors in CoSyne and have since been joined by several notable investors, including Local Globe, Backed VC, Dr Jonathan Milner and Amino Collective.

Next portfolio item